Segall Bryant & Hamill LLC Purchases Shares of 278,201 Ironwood Pharmaceuticals, Inc. $IRWD

Segall Bryant & Hamill LLC bought a new position in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) during the 1st quarter, Holdings Channel reports. The fund bought 278,201 shares of the biotechnology company’s stock, valued at approximately $976,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of IRWD. Bank of America Corp DE lifted its holdings in Ironwood Pharmaceuticals by 248.3% in the 3rd quarter. Bank of America Corp DE now owns 11,695,544 shares of the biotechnology company’s stock worth $15,321,000 after buying an additional 8,337,672 shares during the period. Millennium Management LLC increased its stake in shares of Ironwood Pharmaceuticals by 186.6% during the first quarter. Millennium Management LLC now owns 6,359,682 shares of the biotechnology company’s stock valued at $9,349,000 after buying an additional 4,140,439 shares during the period. AQR Capital Management LLC raised its holdings in shares of Ironwood Pharmaceuticals by 144.3% during the second quarter. AQR Capital Management LLC now owns 6,165,637 shares of the biotechnology company’s stock valued at $4,422,000 after acquiring an additional 3,641,762 shares in the last quarter. Charles Schwab Investment Management Inc. raised its holdings in shares of Ironwood Pharmaceuticals by 1.2% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 4,975,939 shares of the biotechnology company’s stock valued at $16,769,000 after acquiring an additional 58,603 shares in the last quarter. Finally, Marshall Wace LLP lifted its stake in Ironwood Pharmaceuticals by 40.7% in the fourth quarter. Marshall Wace LLP now owns 4,424,002 shares of the biotechnology company’s stock worth $14,909,000 after acquiring an additional 1,279,863 shares during the period.

Insider Activity at Ironwood Pharmaceuticals

In related news, Director Julie Mchugh sold 21,571 shares of the firm’s stock in a transaction that occurred on Tuesday, June 16th. The stock was sold at an average price of $3.73, for a total transaction of $80,459.83. Following the completion of the transaction, the director owned 250,749 shares of the company’s stock, valued at $935,293.77. This trade represents a 7.92% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Ronald Silver sold 127,890 shares of Ironwood Pharmaceuticals stock in a transaction on Tuesday, July 7th. The shares were sold at an average price of $4.52, for a total value of $578,062.80. Following the transaction, the insider owned 313,680 shares of the company’s stock, valued at $1,417,833.60. The trade was a 28.96% decrease in their position. The SEC filing for this sale provides additional information. 9.30% of the stock is currently owned by company insiders.

Ironwood Pharmaceuticals Price Performance

Shares of NASDAQ IRWD opened at $4.15 on Thursday. Ironwood Pharmaceuticals, Inc. has a 1 year low of $0.80 and a 1 year high of $5.78. The stock has a market cap of $676.70 million, a P/E ratio of 6.92 and a beta of 0.20. The firm has a 50-day moving average of $3.87 and a 200 day moving average of $3.97.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last announced its quarterly earnings data on Thursday, May 7th. The biotechnology company reported $0.24 earnings per share for the quarter, missing analysts’ consensus estimates of $0.25 by ($0.01). Ironwood Pharmaceuticals had a negative return on equity of 39.65% and a net margin of 28.26%.The business had revenue of $106.51 million during the quarter, compared to analysts’ expectations of $92.11 million. Research analysts expect that Ironwood Pharmaceuticals, Inc. will post 1.04 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on IRWD. Wall Street Zen upgraded shares of Ironwood Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Sunday, May 17th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Ironwood Pharmaceuticals in a research report on Friday, July 24th. Finally, Zacks Research lowered shares of Ironwood Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Thursday, July 30th. One research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Ironwood Pharmaceuticals currently has a consensus rating of “Hold” and an average target price of $6.23.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc is a commercial‐stage biotechnology company focused on the discovery, development and commercialization of medicines for gastrointestinal (GI) disorders. The company’s flagship product is linaclotide, marketed under the brand name LINZESS in the United States for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). Through a strategic collaboration with Allergan (now part of AbbVie), Ironwood also commercializes linaclotide in select ex-U.S.